| 周海燕,单 莉,何菊仙,樊晓慧,辛 欣.低剂量米非司酮联合戈舍瑞林注射液治疗子宫肌瘤患者效果及对性激素水平的影响[J].现代生物医学进展英文版,2023,(12):2320-2324. |
| 低剂量米非司酮联合戈舍瑞林注射液治疗子宫肌瘤患者效果及对性激素水平的影响 |
| Effect of Low-dose Mifepristone Combined with Goserelin Injection on Patients with Uterine Leiomyoma and Its Influence on Sex Hormone Levels |
| Received:December 06, 2022 Revised:December 31, 2022 |
| DOI：10.13241/j.cnki.pmb.2023.12.022 |
| 中文关键词: 低剂量 米非司酮 戈舍瑞林 子宫肌瘤 性激素 |
| 英文关键词: Low dose Mifepristone Goserellin Fibroid Sex hormone |
| 基金项目:陕西省卫生健康委科研基金项目（2018D039） |
|
| Hits: 646 |
| Download times: 402 |
| 中文摘要: |
| 摘要 目的：探讨低剂量米非司酮联合戈舍瑞林注射液治疗子宫肌瘤患者效果及对性激素水平的影响。方法：选取我院2020年1月到2022年1月收治的90例子宫肌瘤患者，分为对照组、观察A组、观察组B组，每组30例。对照组患者给予戈舍瑞林治疗，观察A组给予常规剂量米非司酮联合戈舍瑞林治疗，观察B组给予低剂量米非司酮联合戈舍瑞林治疗，对比三组患者临床治疗效果，血清促卵泡生成素（FSH）、孕激素（P）、雌二醇（E2）相关性激素水平，降钙素原（PCT）、C反应蛋白（CRP）炎症因子水平以及不良反应情况。结果：三组患者总有效率对比差异显著，观察A组与观察B组较对照组高（P＜0.05），但观察A组与观察B组对比无差异（P＞0.05）；三组患者治疗前血清FSH、P、E2相关性激素水平对比无差异（P＞0.05），治疗后三组均降低，且观察A组与观察B组较对照组低（P＜0.05），但观察A组与观察B组对比无差异（P＞0.05）；治疗后三组患者CRP、PCT相关炎症因子水平均降低，且观察组低于对照组（P＜0.05），且观察A组与观察B组较对照组低（P＜0.05），但观察A组与观察B组对比无差异（P＞0.05）；三组患者不良反应发生率对比差异显著，且观察B组和对照组明显低于观察A组（P＞0.05）。结论：米非司酮联合戈舍瑞林注射液治疗子宫肌瘤疗效显著，均能改善患者炎症反应与性激素水平，但采取低剂量米非司酮联合戈舍瑞林患者不良反应较低，且同时疗效显著，值得临床应用推广。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of low-dose mifepristone combined with goserelin injection in the treatment of uterine leiomyoma and its influence on the level of sex hormones. Methods: 90 patients with hysteromyoma admitted to our hospital from January 2020 to January 2022 were selected as the research objects. All patients were divided into control group, observation group A, and observation group B, with 30 cases in each group, using random number table. The patients in the control group were treated by intravenous injection of goserelin. Observe that group A was treated with conventional dose of mifepristone combined with goserelin, and group B was treated with low-dose of mifepristone combined with goserelin. Compare the clinical treatment effects of the three groups of patients, serum levels of follicle stimulating hormone (FSH), progesterone (P), estradiol (E2) related hormones, procalcitonin (PCT) C-reactive protein (CRP) inflammatory factor level and adverse reactions. Results: The total effective rate of the three groups was different, observation group A and observation group B were higher than the control group (P<0.05), but there was no difference between observation group A and observation group B (P>0.05); There was no difference in the levels of serum FSH, P, E2 related hormones among the three groups before treatment (P>0.05). After treatment, the levels in the three groups decreased, and the levels of observation group A and observation group B were lower than those in the control group (P<0.05), but there was no difference between observation group A and observation group B (P>0.05); After treatment, the levels of CRP and PCT related inflammatory factors in the three groups decreased, and the observation group was lower than the control group (P<0.05), and the observation group A and observation group B were lower than the control group (P<0.05), but there was no difference between the observation group A and observation group B (P>0.05); The incidence of adverse reactions in the three groups was different, and the observation group B and the control group were significantly lower than the observation group A (P>0.05). Conclusion: Mifepristone combined with Goserellin injection has a significant effect in the treatment of uterine leiomyoma, both of which can improve the inflammatory reaction and sex hormone level of patients. However, low-dose Mifepristone combined with Goserellin has a lower adverse reaction and a significant effect, which is worthy of clinical application and promotion. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
